Fed Circ. Revives Mylan Bid To Invalidate Relistor Patent

Law360 (April 8, 2020, 7:49 PM EDT) -- The Federal Circuit revived a Mylan Pharmaceuticals Inc. bid to invalidate the patent for opioid-induced constipation drug Relistor, ruling Wednesday that a lower court was too hasty in finding that the generic company failed to show the brand name drug's formula was obvious.

The three-judge panel's precedential decision reversed summary judgement for units of Valeant Pharmaceuticals in their infringement claims over Mylan's planned generic version of methylnaltrexone. The New Jersey federal court ruled in favor of Valeant after reasoning that Mylan relied on research pertaining to two different compounds other than methylnaltrexone.

But the appeals court sided with Mylan's contention that the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!